These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 1980828)

  • 21. Electroconvulsive therapy and clozapine in adolescents with schizophrenia spectrum disorders: is it a safe and effective combination?
    Flamarique I; Castro-Fornieles J; Garrido JM; de la Serna E; Pons A; Bernardo M; Baeza I
    J Clin Psychopharmacol; 2012 Dec; 32(6):756-66. PubMed ID: 23131877
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Catatonia in a 14 year-old girl: treatment with clorazepam and carbamazepine, a 10-year follow-up].
    Askenazy F; Dor E; Benoit M; Dupuis G; Serret S; Myquel M; Seddiki Y
    Encephale; 2010 Feb; 36(1):46-53. PubMed ID: 20159196
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Electroconvulsive therapy and schizophrenia. Update from the data of the literature].
    Joober R; Bennegadi Z; Olié JP; Lôo H
    Encephale; 1991; 17(4):267-72. PubMed ID: 1683628
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia. Comparison with the atypical neuroleptic, clozapine.
    Litman RE; Su TP; Potter WZ; Hong WW; Pickar D
    Br J Psychiatry; 1996 May; 168(5):571-9. PubMed ID: 8733795
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Psychopathologic changes in chronic schizophrenic patients following withdrawal of neuroleptics: relation to therapeutic, neuroendocrine and computer tomography variables].
    Albus M; Naber D; Ackenheil M; Bürke H; Müller-Spahn F; Münch U; Reinertshofer T; Schmidt-Vanderheyden W; Weber G; Wissmann J
    Fortschr Neurol Psychiatr; 1986 Jan; 54(1):15-20. PubMed ID: 2868983
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Continuation ECT in treatment-resistant schizophrenia: a controlled study.
    Chanpattana W; Chakrabhand ML; Sackeim HA; Kitaroonchai W; Kongsakon R; Techakasem P; Buppanharun W; Tuntirungsee Y; Kirdcharoen N
    J ECT; 1999 Sep; 15(3):178-92. PubMed ID: 10492856
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ECT in schizophrenia: need for reappraisal?
    Saju PJ; Jacob KS
    Br J Psychiatry; 1993 Apr; 162():573-4. PubMed ID: 8097658
    [No Abstract]   [Full Text] [Related]  

  • 28. Lowest effective dose of depot neuroleptics.
    Hoencamp E; Haffmans PJ; Jansen GS
    Br J Psychiatry; 1992 Mar; 160():422-3. PubMed ID: 1348655
    [No Abstract]   [Full Text] [Related]  

  • 29. Impacts of Electroconvulsive Therapy on 1-Year Outcomes in Patients With Schizophrenia: A Controlled, Population-Based Mirror-Image Study.
    Lin HT; Liu SK; Hsieh MH; Chien YL; Chen IM; Liao SC; Tsai HJ; Wu CS
    Schizophr Bull; 2018 Jun; 44(4):798-806. PubMed ID: 29036711
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Electroconvulsive therapy in treatment-resistant schizophrenia: prediction of response and the nature of symptomatic improvement.
    Chanpattana W; Sackeim HA
    J ECT; 2010 Dec; 26(4):289-98. PubMed ID: 20375701
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adjunctive treatments in schizophrenia: pharmacotherapies and electroconvulsive therapy.
    Johns CA; Thompson JW
    Schizophr Bull; 1995; 21(4):607-19. PubMed ID: 8749888
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The application of electroconvulsive therapy in neuroleptic malignant syndrome treatment in patient with catatonic schizophrenia].
    Kucia K; Warchala A
    Wiad Lek; 2005; 58(9-10):572-4. PubMed ID: 16529073
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Leicester ECT trial: results in schizophrenia.
    Brandon S; Cowley P; McDonald C; Neville P; Palmer R; Wellstood-Eason S
    Br J Psychiatry; 1985 Feb; 146():177-83. PubMed ID: 3884080
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is there a decline in cognitive functions after combined electroconvulsive therapy and antipsychotic therapy in treatment-refractory schizophrenia?
    Pawełczyk A; Kołodziej-Kowalska E; Pawełczyk T; Rabe-Jabłońska J
    J Nerv Ment Dis; 2015 Mar; 203(3):182-6. PubMed ID: 25668655
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A double-blind controlled study of intramuscular zuclopenthixol acetate and liquid oral haloperidol in the treatment of schizophrenic patients with acute exacerbation.
    Chouinard G; Safadi G; Beauclair L
    J Clin Psychopharmacol; 1994 Dec; 14(6):377-84. PubMed ID: 7884017
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characteristics of schizophrenic patients and the outcome of fluphenazine and of electroconvulsive treatments.
    Landmark J; Joseph L; Merskey H
    Can J Psychiatry; 1987 Aug; 32(6):425-8. PubMed ID: 3690470
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk for definite neuroleptic malignant syndrome. A prospective study in 223 consecutive in-patients.
    Hermesh H; Aizenberg D; Weizman A; Lapidot M; Mayor C; Munitz H
    Br J Psychiatry; 1992 Aug; 161():254-7. PubMed ID: 1355693
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Use of ECT in drug-refractory schizophrenia--a survey of the current literature].
    Lehnhardt FG; Konkol C; Kuhn J
    Fortschr Neurol Psychiatr; 2012 Sep; 80(9):501-11. PubMed ID: 22706802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Maintenance ECT in treatment-resistant schizophrenia.
    Chanpattana W
    J Med Assoc Thai; 2000 Jun; 83(6):657-62. PubMed ID: 10932493
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities.
    Citrome L; Jaffe A; Levine J
    Schizophr Res; 2010 Jun; 119(1-3):153-9. PubMed ID: 20347267
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.